Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease

Transplantation

Volumn 65, Issue 2, 1998, Pages 264-268

  Randhawa, Parmjeet S ^a,b   Whiteside, Theresa L ^c   Zeevi, Adriana ^a   Elder, Elaine M ^c   Rao, Abdul S ^a   Demetris, Anthony J ^a   Weng, Xue ^a   Valdivia, Luis A ^a   Rakela, Jorge ^a   Nalesnik, Michael A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CULTURE; CELL GROWTH; COMBINED IMMUNODEFICIENCY; DISEASE ASSOCIATION; DISEASE SEVERITY; HLA SYSTEM; IMMUNOTHERAPY; LYMPHOBLASTOID CELL; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032570278     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801270-00022     Document Type: Article

References (32)

1. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173.
2. Hanto DW, Frizerra G, Gajl-Peczaska KJ, Balfour HH, Simmons RL, Najarian JS. Acyclovir therapy of Epstein-Barr virus induced posttransplantation lymphoproliferative diseases. Transplant Proc 1985; 17: 89.
3. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 2: 552.
4. Ippoliti G, Martinelli L, Lorenzutti F, et al. Post-transplant lymphoproliferative disease after heart transplantation on Sandimmune therapy: treatment with interferon alfa-2b and intravenous immunoglobulin. Transplant Proc 1994; 26: 2660.
5. Taguchi Y, Purtilo DT, Okano M. The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus induced lymphoproliferative disorder in a liver transplant recipient. Transplant 1994; 57: 1813.
6. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185.
7. Porter DL, Orloff GJ, Antin JH, Hanto DW, Shapiro RS, Filipovich AM. Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sei 1994; 4: 12.
8. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9.
9. - lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63: 1200.
10. Shapiro RS, Chauvenet A, McGuire W, Pearson A, McGlave P. Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gamma globulin. N Engl J Med 1988; 322: 1334.
11. Shepherd JD, Gascoyne RD, Barnett MJ, Coghlan JD, Phillips GL. Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639.
12. Faro A, Kurland G, Michaels MG, et al. Interferon alpha affects the immune response in post-transplant lymphoproliferative disorder. Am J Respir Crit Care Med 1996; 153: 1442.
13. Randhawa PS, Zeevi A, Alvares C, et al. Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease. In Vitro Cell Dev Biol 1994; 30A: 400.
14. Randhawa PS, Whiteside TA, Zeevi A, et al. In vitro culture of B-lymphocytes derived from Epstein-Barr virus associated post-transplant lymphoproliferative disease: cytokine production and effect of interferon alpha. In Vitro Cell Dev Biol 1997; 33: 803.
15. Rochford R, Hobbs MV, Garnier JL, Coooper NR, Cannon MJ. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci USA 1992; 90: 352.
16. Cen CA, Williams PA, McWilliam MP, Breinig MC, Ho M, McKnight JLC. Evidence for restricted EBV latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with PTLD. Blood 1993; 81: 1393.
17. Mentzer SJ, Longtine J, Fingeroth J, et al. Immunoblastic lymphoma of donor origin in the allograft after lung transplantation. Transplantation 1996; 61: 1720.
18. Yoshizawa K, Kiyosawa K, Yamada S, et al. Establishment of Epstein-Barr virus-associated lymphoma cell line SUBL with t (2;3) (pll;q27) from a liver transplant patient. Cancer Genet Cytogenet 1993; 71: 155.
19. 2. Proc Natl Acad Sci USA 1988; 85: 8037.
20. Lotz M, Tsoukas CD, Fong S, Carson DA, Vaughan JH. Regulation of Epstein-Barr virus infection by recombinant interferons: selected sensitivity to interferon-γ. Eur J Immunol 1985; 15: 520.
21. Lee SH, Kelley S, Chiu H, Stebbing N. Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon sub-types. Cancer Res 1982; 42: 1312.
22. Swaminathan S, Huneycutt BS, Reiss CS, Kieff E. Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes. J Virol 1992; 66: 5133.
23. Trown PW, Wills RJ, Kamm JJ. The preclinical development of roferon-A. Cancer 1986; 57: 1648.
24. Jonak GJ, Friedland BK, Anton ED, Knight E. Regulation of c-myc RNA and its proteins in Daudi cells by interferon-β. J Interferon Res 1987; 7: 41.
25. Heslop HE, Bianchi ACM, Cordingley FT, et al. Effects of interferon α on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 1990; 172: 1729.
26. Clarke PA, Sharp NA, Arrand JR, Clemens MJ. Epstein-Barr virus gene expression in interferon-treated cells: implications for the regulation of protein synthesis and the antiviral state. Biochim Biophys Acta 1990; 1050: 167.
27. Maeyer ED, Maeyer-Guignard JD. Interferons. In: Thomson A, ed. The cytokine handbook. San Diego: Academic Press, 1991: 215.
28. Exley R, Gordon J, Nathan P, Walker L, Clemens MJ. Antiproliferative effects of interferons on Daudi Burkitt lymphoma cells: induction of cell differentiation and loss of response to autocrine growth factors. Int J Cancer 1987; 40: 53.
29. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reily RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 SCID/SCID mice. J Exp Med 1996; 183: 1215.
30. Boyle TJ, Berend KR, DiMaio M, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 1993; 114: 218.
31. Baiocchi RA, Caliguiri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/SCID mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1994; 91: 5577.
32. - T-cell responses are suppressed. Immunology 1991; 73: 444.